Howard Hughes Medical Institute bought a new stake in Salesforce.com Inc (NYSE:CRM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,361 shares of the CRM provider’s stock, valued at approximately $378,000.

Other institutional investors have also recently bought and sold shares of the company. Appropriate Balance Financial Services Inc. grew its holdings in Salesforce.com by 6.9% in the second quarter. Appropriate Balance Financial Services Inc. now owns 513 shares of the CRM provider’s stock valued at $5,928,000 after purchasing an additional 33 shares during the last quarter. Capital Analysts LLC grew its holdings in Salesforce.com by 14.1% in the second quarter. Capital Analysts LLC now owns 1,266 shares of the CRM provider’s stock valued at $110,000 after purchasing an additional 156 shares during the last quarter. Peddock Capital Advisors LLC grew its holdings in Salesforce.com by 3,000.0% in the second quarter. Peddock Capital Advisors LLC now owns 1,395 shares of the CRM provider’s stock valued at $121,000 after purchasing an additional 1,350 shares during the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Salesforce.com in the second quarter valued at $130,000. Finally, First Personal Financial Services grew its holdings in Salesforce.com by 7.5% in the first quarter. First Personal Financial Services now owns 1,611 shares of the CRM provider’s stock valued at $133,000 after purchasing an additional 112 shares during the last quarter. 86.98% of the stock is currently owned by institutional investors.

Shares of Salesforce.com Inc (CRM) traded down 0.70% during trading on Friday, hitting $94.63. The stock had a trading volume of 6,081,706 shares. Salesforce.com Inc has a 52 week low of $66.43 and a 52 week high of $98.22. The stock’s 50 day moving average is $92.86 and its 200 day moving average is $88.04. The stock’s market capitalization is $68.01 billion.

Salesforce.com (NYSE:CRM) last announced its earnings results on Tuesday, August 22nd. The CRM provider reported $0.33 EPS for the quarter, topping the consensus estimate of $0.09 by $0.24. Salesforce.com had a positive return on equity of 1.83% and a negative net margin of 0.85%. The business had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.52 billion. During the same period in the previous year, the business earned $0.24 EPS. Salesforce.com’s revenue was up 25.7% compared to the same quarter last year. On average, equities research analysts expect that Salesforce.com Inc will post $1.32 earnings per share for the current fiscal year.

In other Salesforce.com news, insider Parker Harris sold 8,027 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $87.27, for a total transaction of $700,516.29. Following the transaction, the insider now owns 49,913 shares of the company’s stock, valued at approximately $4,355,907.51. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Chairman Marc Benioff sold 20,000 shares of the company’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $86.81, for a total value of $1,736,200.00. Following the transaction, the chairman now directly owns 34,195,300 shares in the company, valued at approximately $2,968,493,993. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 677,159 shares of company stock worth $61,111,134. Company insiders own 6.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: “4,361 Shares in Salesforce.com Inc (CRM) Acquired by Howard Hughes Medical Institute” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/17/4361-shares-in-salesforce-com-inc-crm-acquired-by-howard-hughes-medical-institute.html.

Several analysts have weighed in on the company. Northland Securities set a $105.00 target price on Salesforce.com and gave the company a “buy” rating in a report on Saturday, June 24th. Jefferies Group LLC reissued a “hold” rating and issued a $80.00 target price on shares of Salesforce.com in a report on Monday, May 22nd. BTIG Research restated a “buy” rating and issued a $100.00 price objective on shares of Salesforce.com in a research report on Monday, May 22nd. Robert W. Baird restated a “buy” rating and issued a $110.00 price objective (up from $100.00) on shares of Salesforce.com in a research report on Wednesday, August 23rd. Finally, Drexel Hamilton restated a “buy” rating and issued a $111.00 price objective on shares of Salesforce.com in a research report on Wednesday, August 23rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and forty-seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $102.28.

Salesforce.com Company Profile

Salesforce.com, inc. is a provider of enterprise software, delivered through the cloud, with a focus on customer relationship management (CRM). The Company focuses on cloud, mobile, social, Internet of Things (IoT) and artificial intelligence technologies. The Company’s service offerings are configured and integrated with other platforms and enterprise applications.

Want to see what other hedge funds are holding CRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Salesforce.com Inc (NYSE:CRM).

Institutional Ownership by Quarter for Salesforce.com (NYSE:CRM)

Receive News & Stock Ratings for Salesforce.com Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salesforce.com Inc and related stocks with our FREE daily email newsletter.